The Trump Administration Must Protect Patient Access to Advanced Wound Care
Summary: This opinion piece by Martha Kelso and Rajendra S. Gogia criticizes the Trump administration’s proposed CMS rulemaking to slash reimbursement for advanced wound care therapies, arguing it threatens millions with chronic wounds by ignoring their evidence-based benefits in reducing infections, amputations, and costs. Affecting 25 million Americans (including 6.5 million at any time), these treatments—like bio-engineered substitutes and cellular products—shorten recovery and prevent complications, yet face arbitrary cuts amid fraud concerns. The authors call for smarter reforms: AI-aided billing, accreditation, national coverage determinations, and outcomes registries to balance costs with innovation, noting Trump’s own venous insufficiency as a personal stake in preserving access.
Key Highlights:
- Chronic wounds cost billions; advanced care saves money by avoiding hospitalizations/amputations, but proposed cuts risk exacerbating this.
- Misconceptions: Treatments aren’t wasteful; fraud should be tackled with AI verification, not blanket reductions punishing patients.
- Policy fixes: National Coverage Determination for uniform access; AI for medical necessity docs; provider accreditation; national registries for accountability.
- Patient impact: 15% of Medicare beneficiaries affected; delays in care lead to pain, disability, and higher long-term expenses.
- Personal note: Trump’s venous insufficiency highlights need; urges reversal to protect vulnerable populations.
Keywords: advanced wound care, CMS reimbursement, chronic wounds, cellular products, wound care policy